KLN Delivers Sustained Growth in Revenue and Core Net Profit
HONG KONG, Aug. 28, 2026 /PRNewswire/ -- KLN Logistics Group Limited ('KLN' or together with its subsidiaries, the 'Group'; Stock Code 0636.HK) today announced the Group's interim results for the six months ended 30 June 2026. Group's Financial...
Ulike Brings "Future Beauty, Powered by Light" to Boston, Challenging the Conventional Beauty Trade-Off Between Efficacy and Comfort
Nobel Prize-winning scientist Dr. Ardem Patapoutian, Harvard Associate Professor Dr. Anna Mandinova, actress, wellness advocate, and entrepreneur Sasha Pieterse, and PCOSAA CEO Megan Stewart joined Ulike to redefine the standard of beauty. BOSTON,...
Leifras Celebrates 25th Anniversary, Setting Vision for Becoming Global Infrastructure Through "Sports and Social"
Operating Across All 47 Prefectures in Japan, Ranking No. 1 in School Club Activity Support (According to Tokyo Shoko Research, as of December 2025) with Over 70,000 Sports School Members. Following Its Nasdaq Listing, Leifras Sets Vision for the...
GeeLark Expands Its AIGC Suite and Opens AI Content Creation to Free Users
SINGAPORE, Aug. 28, 2026 /PRNewswire/ -- GeeLark today announced a major expansion of its AIGC capabilities, introducing new AI models and editing tools for social media content creation. Previously available only to paid users, GeeLark AIGC can now...
Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers
TSY-110 is positioned to become the first biosimilar alternative to Roche's Kadcyla® (ado-trastuzumab emtansine) in major regulated markets. TAIPEI, Aug. 28, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWSE: 6838), today announced the...
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
Memorandum of Understanding establishes a framework for joint development of clinical trial simulation capabilities The partnership unites global clinical operations excellence with advanced digital twin technology, delivering simulation-first drug...
Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma
SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2026 Semi-Annual Report, showing comprehensive progress across all business segments. With the gradual realization of commercial launch and international expansion...
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and...